1. Home
  2. MGNI vs AMRX Comparison

MGNI vs AMRX Comparison

Compare MGNI & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNI
  • AMRX
  • Stock Information
  • Founded
  • MGNI 2007
  • AMRX 2002
  • Country
  • MGNI United States
  • AMRX United States
  • Employees
  • MGNI N/A
  • AMRX N/A
  • Industry
  • MGNI Computer Software: Programming Data Processing
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGNI Technology
  • AMRX Health Care
  • Exchange
  • MGNI Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • MGNI 2.5B
  • AMRX 2.4B
  • IPO Year
  • MGNI N/A
  • AMRX N/A
  • Fundamental
  • Price
  • MGNI $17.68
  • AMRX $7.83
  • Analyst Decision
  • MGNI Strong Buy
  • AMRX Strong Buy
  • Analyst Count
  • MGNI 14
  • AMRX 5
  • Target Price
  • MGNI $18.39
  • AMRX $10.00
  • AVG Volume (30 Days)
  • MGNI 2.8M
  • AMRX 1.0M
  • Earning Date
  • MGNI 02-26-2025
  • AMRX 02-28-2025
  • Dividend Yield
  • MGNI N/A
  • AMRX N/A
  • EPS Growth
  • MGNI N/A
  • AMRX N/A
  • EPS
  • MGNI 0.12
  • AMRX N/A
  • Revenue
  • MGNI $661,134,000.00
  • AMRX $2,680,420,000.00
  • Revenue This Year
  • MGNI $0.57
  • AMRX $18.06
  • Revenue Next Year
  • MGNI $10.16
  • AMRX $3.82
  • P/E Ratio
  • MGNI $148.63
  • AMRX N/A
  • Revenue Growth
  • MGNI 8.71
  • AMRX 12.32
  • 52 Week Low
  • MGNI $8.38
  • AMRX $5.01
  • 52 Week High
  • MGNI $21.29
  • AMRX $9.48
  • Technical
  • Relative Strength Index (RSI)
  • MGNI 46.04
  • AMRX 42.03
  • Support Level
  • MGNI $17.31
  • AMRX $7.66
  • Resistance Level
  • MGNI $20.06
  • AMRX $7.95
  • Average True Range (ATR)
  • MGNI 1.17
  • AMRX 0.21
  • MACD
  • MGNI -0.21
  • AMRX -0.03
  • Stochastic Oscillator
  • MGNI 28.37
  • AMRX 29.92

About MGNI Magnite Inc.

Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: